ANIX Anixa Biosciences, Inc.
Healthcare$2.73-2.15%ClosedMarket Cap: $91.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.15
P/S
0.00
EV/EBITDA
-8.36
DCF Value
$0.03
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.6%
ROA
-67.7%
ROIC
-78.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.7M | $-2.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-2.9M | $-2.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-11.7M | $-10.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.4M | $-2.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.0M | $-2.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.4M | $-3.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.2M | $-2.9M | $— | — |
| FY null | $0.00 | NaN% | $-13.8M | $-12.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.6M | $-3.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.6M | $-3.3M | $— | — |
| Q1 2024 | $0.00 | NaN% | $-3.6M | $-3.3M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-3.1M | $-2.7M | $-0.09 | — |